Cour
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Illinois, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
8045 Lamon Ave Ste 1202, Skokie, Illinoi...Website
www.courpharma.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Cour
COUR Pharma is a clinical-stage biotechnology company developing first-in-class antigen-specific immune tolerance therapies for autoimmune diseases. COUR’s therapies are developed using a proprietary antigen-specific immune tolerance nanoparticle platform. COUR nanoparticles encapsulate disease-specific antigens and have been designed with specific features to mimic the anti-inflammatory nature of apoptotic cells. COUR’s nanoparticles work to address the complexity of autoimmunity at its source, reprogramming upstream pathways to induce tolerance toward specific, disease-relevant autoantigens. Data from multiple clinical and preclinical programs have demonstrated the ability of COUR’s product candidates to induce antigen-specific immune tolerance, with the potential to treat a wide range of autoimmune diseases.Explore more
Cour Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cour your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cour
Check out if Cour is spiking on competitors!
Product Launch: Get notified when Cour launches new products
Check if Cour has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cour had a recent Job posting/layoffs
Earning: See what the market has to say on Cour recently announced quarterly report
Funding: Get notified immidiatlly once Cour has new funding data
Cour, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cour
Compare insights from companies similar to Cour, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cour financials insights
Gather financial insights about Cour, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Unspecified
$30M
2024
Series A
$105M
2026
Series B
$50M
Cour Tech Stack
A closer look at the technologies used by Cour
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
, according to a front-line source in product development, is in the midst of initiatives related to quality assurance. The organization is currently evaluating MasterControl QMS. Cour Pharmaceuticals will be increasing funding and is expected to increase permanent employee workforce to support these efforts. The organization is focused on therapeutics in this area.
Spending/Investment, Quality Assurance, Product Development, Financial Planning, Product Management, Pharmaceuticals
Project
, according to a front-line source in product development, has completed initiatives related to web development within the last twelve months.
Collaboration/Web Apps, Application Development, Product Development, Website, Product Management
Project
, according to a front-line source in product development, began leveraging GitHub Copilot within the last six to twelve months. Cour Pharmaceuticals is leveraging this solution for analytic insights (e.g., predictive, strategic, etc.), root cause analysis (RCA), and natural language interfaces.
Product Development, Product Management, Pharmaceuticals, Language
Project
Product Development, Product Management, Pharmaceuticals, Language
Cour News & Media
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
CHICAGO, March 03, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, today announced positive one-year results from its Phase 2a study evaluating CNP-104 as a potential treatment for patients with Primary Biliary Cholangitis (PBC).COUR Pharma Publishes Peer-Reviewed Data in Science Advances
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune toleranceCOUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CNP-106, an investigational therapy for the treatment of generalized myasthenia gravis (gMG).COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial for CNP-103, a tolerogenic nanoparticle therapy in development to address the underlying autoimmunity associated with type 1 diabetes (T1D).
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cour
Sign Up For FreeTo access detailed company insights
COUR Pharma is a clinical-stage biotechnology company developing first-in-class antigen-specific immune tolerance therapies for autoimmune diseases. COUR’s therapies are developed using a proprietary antigen-specific immune tolerance nanoparticle platform. COUR nanoparticles encapsulate disease-specific antigens and have been designed with specific... Read More
